SWTX Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -169.47% compared to SpringWorks Therapeutics's net margin of -10220.14%. SpringWorks Therapeutics's return on equity of -49.69% beat Cytokinetics's return on equity of --.

SpringWorks Therapeutics has a consensus price target of $47.00, signalling upside risk potential of 0.54%. On the other hand Cytokinetics has an analysts' consensus of $73.45 which suggests that it could grow by 126.63%. Given that Cytokinetics has higher upside potential than SpringWorks Therapeutics, analysts believe Cytokinetics is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.699, which suggesting that the stock is 30.122% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.592, suggesting its less volatile than the S&P 500 by 40.762%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.1M, which are larger than Cytokinetics quarterly revenues of $1.6M. SpringWorks Therapeutics's net income of -$83.2M is higher than Cytokinetics's net income of -$161.4M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.84x versus 195.43x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Regulus Therapeutics has a net margin of -169.47% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -49.69% beat Regulus Therapeutics's return on equity of --.

SpringWorks Therapeutics has a consensus price target of $47.00, signalling upside risk potential of 0.54%. On the other hand Regulus Therapeutics has an analysts' consensus of $8.80 which suggests that it could grow by 10.41%. Given that Regulus Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Regulus Therapeutics is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.699, which suggesting that the stock is 30.122% less volatile than S&P 500. In comparison Regulus Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.643%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regulus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Regulus Therapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.1M, which are larger than Regulus Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$83.2M is lower than Regulus Therapeutics's net income of -$9.6M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Regulus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.84x versus -- for Regulus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -169.47% compared to SpringWorks Therapeutics's net margin of 23.33%. SpringWorks Therapeutics's return on equity of -49.69% beat Vertex Pharmaceuticals's return on equity of -6.04%.

SpringWorks Therapeutics has a consensus price target of $47.00, signalling upside risk potential of 0.54%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 12.02%. Given that Vertex Pharmaceuticals has higher upside potential than SpringWorks Therapeutics, analysts believe Vertex Pharmaceuticals is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.699, which suggesting that the stock is 30.122% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.1M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. SpringWorks Therapeutics's net income of -$83.2M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.84x versus 10.42x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -169.47% compared to SpringWorks Therapeutics's net margin of -2828.67%. SpringWorks Therapeutics's return on equity of -49.69% beat Catheter Precision's return on equity of -137.84%.

SpringWorks Therapeutics has a consensus price target of $47.00, signalling upside risk potential of 0.54%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 919.37%. Given that Catheter Precision has higher upside potential than SpringWorks Therapeutics, analysts believe Catheter Precision is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.699, which suggesting that the stock is 30.122% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.850, suggesting its less volatile than the S&P 500 by 184.968%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.1M, which are larger than Catheter Precision quarterly revenues of $143K. SpringWorks Therapeutics's net income of -$83.2M is lower than Catheter Precision's net income of -$4M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.84x versus 2.25x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.